Ncongwane said he had followed the ad hoc’s committee discussion on the parliamentary TV channel and picked up that MPs were “merely ticking the boxes” and there was no intention to vociferously engage with the questionnaires submitted by candidates.
Results of the phase 3 PRIME study showed that treatment with niraparib with an individualized starting dose significantly extended progression-free survival (PFS) and reduced the risk of disease progression or death by 55% compared with placebo.